Simultaneous double-culprit in-stent thrombosis. Who is the guilty prisoner behind bars: drug-eluting stent, bare-metal stent, or indication for treatment?

Cardiovascular Revascularization Medicine

Volumn 7, Issue 4, 2006, Pages 258-263

  Mezzapelle, Giuseppe ^a   Baglini, Roberto ^b   Baldari, Duccio ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

Acute stent thrombosis; Antithrombin III deficiency; Double platelets antiaggregation

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN;

ADULT; ANTITHROMBIN III DEFICIENCY; ARTICLE; BALLOON DILATATION; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; HEART INFARCTION; HUMAN; HYPERTENSION; IN STENT THROMBOSIS; INTRAVASCULAR ULTRASOUND; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SAFETY; SYMPTOM; THROMBOSIS;

ANTITHROMBIN III DEFICIENCY; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK FACTORS; STENTS; TICLOPIDINE;

EID: 33845447363     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2006.06.001     Document Type: Article

References (19)

1. Fischman D., Leon M., Baim D., Schatz R., Savage M., Penn I., Detre K., Veltri L., Ricci D., Nobuyoshi M., et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med 331 (1994) 496-501
2. Schofer J., Schluter M., Gershlick A., Wijns W., Garcia E., Schampaert E., Breithardt G., and E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-bind, randomized controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
3. Greenberg D., Bakhai A., and Cohen D. Can we afford to eliminate restenosis? Can we afford no to?. J Am Coll Cardiol 43 (2004) 513-518
4. Serruys P., Strauss B., Beatt K., Bertrand M., Puel J., Rickards A., Meier B., Goy J., Vogt P., Kappenberger L., et al. Angiographic follow-up after placement of a self expanding coronary artery stent. N Engl J Med 324 (1991) 13-17
5. Moussa I., Di Mario C., Reimers B., Akiyama T., Tobis J., and Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors, and clinical outcome. J Am Coll Cardiol 29 (1997) 6-12
6. Bertrand M., Legrand V., Boland J., Fleck E., Bonnier J., Emmanuelson H., Vrolix M., Missault L., Chierchia S., Casaccia M., Niccoli L., Oto A., White C., Webb-Peploe M., Van Belle E., and McFadden E. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation 98 (1998) 1507-1603
7. Cutlip D., Baim D., Ho K., Popma J., Lansky A., Cohen D., Carrozza J., Chauhan M., Rodriguez O., and Kuntz R. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 (2001) 1967-1971
8. Lee S., Park S., Hong M., Kim Y., Lee B., Song J., Han K., Lee C., Kang D., Song J., Kim J., and Park S. Triple versus dual antiplatelet therapy after coronary stenting. Impact on stent thrombosis. J Am Coll Cardiol 46 (2005) 1833-1837
9. Bavry A., Kumbhani D., and Helton T. What is the risk of stent thrombosis associated with the use of paclitaxel drug eluting stents for percutaneous coronary interventions?. J Am Coll Cardiol 45 (2005) 941-946
10. Bolognese L. Attività dei laboratori di emodinamica italiani nel 2004. Il Giornale Italiano di Cardiologia Invasiva 2005; (Suppl 2), 3-7.
11. American Heart Association. Heart disease and stroke statistics 2003 update (2002), American Heart Association, Dallas (TX)
12. Gurbel P., Callahan K., Malinin A., Serebruany V., and Gillis J. Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) study. J Invasive Cardiol 14 (2002) 584-589
13. FDA public health web notification: information for physicians on subacute thrombosis (SAT) and hypersensitivity reactions with the use of the Cordis CYPHER coronary stent. US Food and Drug Administration, 2003.
14. Silva J., Ramee S., White C., Collins T., Jenkins J., Nunez E., Zhang S., and Jain S. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J 138 (1999) 446-455
15. Cheneau E., Leborgne L., Mintz G., Kotani J., Pichard A., Satler L., Canos D., Castagna M., Weissman N., and Waksman R. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 108 (2003) 43-47
16. Uren N., Schwarzacher S., Metz J., Lee D., Honda Y., Yeung A., Fitzgerald P., Yock P., and POST Registry Investigators. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur Heart J 23 (2002) 124-132
17. Farb A., Burke A., Kolodgie F., and Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 14 (2003) 1701-1706
18. Finn A., Kolodgie F., Harnek J., Guerrero L., Acampado E., Tefera K., Skorija K., Weber D., Gold H., and Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 2 (2005) 270-278
19. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., Michev I., Corvaja N., Briguori C., Gerckens U., Grube E., and Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 17 (2005) 2126-2130